SG11202103134TA - Nitroxoline prodrug and use thereof - Google Patents
Nitroxoline prodrug and use thereofInfo
- Publication number
- SG11202103134TA SG11202103134TA SG11202103134TA SG11202103134TA SG11202103134TA SG 11202103134T A SG11202103134T A SG 11202103134TA SG 11202103134T A SG11202103134T A SG 11202103134TA SG 11202103134T A SG11202103134T A SG 11202103134TA SG 11202103134T A SG11202103134T A SG 11202103134TA
- Authority
- SG
- Singapore
- Prior art keywords
- nitroxoline
- prodrug
- nitroxoline prodrug
- Prior art date
Links
- RJIWZDNTCBHXAL-UHFFFAOYSA-N nitroxoline Chemical compound C1=CN=C2C(O)=CC=C([N+]([O-])=O)C2=C1 RJIWZDNTCBHXAL-UHFFFAOYSA-N 0.000 title 1
- 229960005131 nitroxoline Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/32—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/32—Esters
- C07D215/34—Carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811148314 | 2018-09-29 | ||
| PCT/CN2019/108419 WO2020063824A1 (en) | 2018-09-29 | 2019-09-27 | Nitroxoline prodrug and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103134TA true SG11202103134TA (en) | 2021-04-29 |
Family
ID=69953367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103134TA SG11202103134TA (en) | 2018-09-29 | 2019-09-27 | Nitroxoline prodrug and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210363165A1 (en) |
| EP (1) | EP3858814A4 (en) |
| JP (1) | JP2022502510A (en) |
| KR (1) | KR20210070320A (en) |
| CN (1) | CN111295372B (en) |
| AU (1) | AU2019351494A1 (en) |
| BR (1) | BR112021005941A2 (en) |
| CA (1) | CA3113463A1 (en) |
| MX (1) | MX2021003724A (en) |
| SG (1) | SG11202103134TA (en) |
| WO (1) | WO2020063824A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402388A (en) * | 2019-08-05 | 2021-02-26 | 江苏亚虹医药科技股份有限公司 | Oral solid preparation for treating bladder cancer and preparation method thereof |
| MX2022011768A (en) * | 2020-03-30 | 2022-10-18 | Jiangsu Yahong Meditech Co Ltd | Crystal form of nitroxoline prodrug, pharmaceutical composition containing same, and preparation method therefor and application thereof. |
| CN111514142B (en) * | 2020-05-29 | 2021-04-06 | 江苏亚虹医药科技股份有限公司 | Pharmaceutical composition containing nitroxoline prodrug and preparation method and application thereof |
| CN111646936A (en) | 2020-06-22 | 2020-09-11 | 江苏亚虹医药科技有限公司 | Process for producing aromatic ether compound |
| CN111773193A (en) * | 2020-07-03 | 2020-10-16 | 江苏亚虹医药科技有限公司 | Pharmaceutical composition containing nitroxoline lysine salt and preparation method and application thereof |
| CN114437033A (en) * | 2020-10-30 | 2022-05-06 | 江苏亚虹医药科技股份有限公司 | Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt |
| CN112745334B (en) * | 2021-02-07 | 2022-03-25 | 厦门一先药业有限公司 | Prodrugs of Barosavir and derivatives thereof, preparation method and application thereof |
| WO2022253159A1 (en) | 2021-05-31 | 2022-12-08 | 江苏亚虹医药科技股份有限公司 | Use of 5-nitro-8-hydroxyquinoline |
| CN118059101A (en) * | 2022-11-22 | 2024-05-24 | 江苏亚虹医药科技股份有限公司 | Use of 8-hydroxyquinoline derivatives |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA883837A (en) * | 1971-10-19 | Societe D'etudes De Produits Chimiques | Furoic esters of 5-nitro quinoline and to methods of preparing them | |
| FR1510067A (en) * | 1966-12-06 | 1968-01-19 | Carbamic esters derived from quinoline | |
| GB1168307A (en) * | 1967-08-14 | 1969-10-22 | Soc D Etudes Prod Chimique | Novel Esters of 5-Nitro-Quinoline |
| FR2197512B1 (en) * | 1972-08-31 | 1977-01-14 | Roussel Uclaf | |
| US3828056A (en) * | 1972-09-11 | 1974-08-06 | Searle & Co | (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers |
| FR2355829A1 (en) * | 1976-06-24 | 1978-01-20 | Debat Lab | Esters of nitroxoline with (poly)carboxylic or (poly)sulphonic acids - useful as antibacterials and antifungals |
| DE3225169A1 (en) * | 1982-07-06 | 1984-01-12 | Basf Ag, 6700 Ludwigshafen | CHINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE MICROBICIDES CONTAINING THEM AND THEIR USE FOR CONTROLLING FUNGI |
| US4472404A (en) * | 1982-08-16 | 1984-09-18 | The Dow Chemical Company | 8-Quinolinyl carbamates and their use as urinary tract antimicrobials |
| ATE55993T1 (en) * | 1983-10-18 | 1990-09-15 | Ciba Geigy Ag | USE OF QUINOLINE DERIVATIVES TO PROTECT CROPS. |
| DE3621540A1 (en) * | 1986-06-27 | 1988-01-07 | Basf Ag | CHINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE MICROBICIDES CONTAINING THE SAME AND THE USE THEREOF FOR CONTROLLING BACTERIA AND MUSHROOMS |
| WO1993020094A1 (en) * | 1992-03-27 | 1993-10-14 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for quinoline |
| WO1999051613A1 (en) * | 1998-04-03 | 1999-10-14 | Medivir Ab | Prodrugs of phosphorous-containing pharmaceuticals |
| IT1317735B1 (en) * | 2000-01-26 | 2003-07-15 | Nicox Sa | SALTS OF ANTIMICROBIAL AGENTS. |
| CA2626627C (en) * | 2005-10-20 | 2012-12-18 | California Pacific Medical Center | Androsterone derivatives and method of use thereof |
| RU2430089C2 (en) * | 2007-03-09 | 2011-09-27 | Грин Кросс Корпорейшн | Orally bioavailable prodrugs of (+)-3-hydroxymorphinan for preventing or treating parkinson's disease |
| US20100078393A1 (en) * | 2008-10-01 | 2010-04-01 | Bei Yin | Biocidal compositions and methods of use |
| WO2010042163A2 (en) * | 2008-10-06 | 2010-04-15 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
| CN101880239A (en) * | 2009-05-08 | 2010-11-10 | 北京美倍他药物研究有限公司 | Water-soluble amino-acid ester derivative of propofol |
| GB201005589D0 (en) * | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| CN102464631B (en) * | 2010-11-08 | 2016-08-10 | 中国科学院上海药物研究所 | Piperazine substituted 1,3-2-substituted carbamide compounds and the substituted amides compound of piperazine and its production and use |
| WO2014145723A1 (en) * | 2013-03-15 | 2014-09-18 | Ke Pan | Base addition salts of nitroxoline and uses thereof |
| CA2911845C (en) * | 2013-05-09 | 2019-08-13 | Sichuan Haisco Pharmaceutical Co., Ltd. | Phenol derivative and preparation method and use in medicine thereof |
| AU2014374603B2 (en) * | 2013-12-30 | 2019-06-06 | Yungjin Pharm. Co., Ltd. | 1,2-naphthoquinone derivative and method for preparing same |
| US10851123B2 (en) * | 2016-02-23 | 2020-12-01 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| WO2017210489A1 (en) * | 2016-06-01 | 2017-12-07 | M3 Biotechnology, Inc. | Compounds |
| MX2022011768A (en) * | 2020-03-30 | 2022-10-18 | Jiangsu Yahong Meditech Co Ltd | Crystal form of nitroxoline prodrug, pharmaceutical composition containing same, and preparation method therefor and application thereof. |
-
2019
- 2019-09-27 MX MX2021003724A patent/MX2021003724A/en unknown
- 2019-09-27 AU AU2019351494A patent/AU2019351494A1/en active Pending
- 2019-09-27 KR KR1020217012529A patent/KR20210070320A/en active Search and Examination
- 2019-09-27 CN CN201980004913.1A patent/CN111295372B/en active Active
- 2019-09-27 CA CA3113463A patent/CA3113463A1/en active Pending
- 2019-09-27 SG SG11202103134TA patent/SG11202103134TA/en unknown
- 2019-09-27 BR BR112021005941-5A patent/BR112021005941A2/en unknown
- 2019-09-27 WO PCT/CN2019/108419 patent/WO2020063824A1/en active Application Filing
- 2019-09-27 EP EP19864911.3A patent/EP3858814A4/en active Pending
- 2019-09-27 US US17/280,999 patent/US20210363165A1/en active Pending
- 2019-09-27 JP JP2021542249A patent/JP2022502510A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111295372B (en) | 2021-03-09 |
| MX2021003724A (en) | 2021-05-14 |
| US20210363165A1 (en) | 2021-11-25 |
| JP2022502510A (en) | 2022-01-11 |
| CA3113463A1 (en) | 2020-04-02 |
| BR112021005941A2 (en) | 2021-06-29 |
| AU2019351494A1 (en) | 2021-05-20 |
| WO2020063824A1 (en) | 2020-04-02 |
| EP3858814A4 (en) | 2022-10-05 |
| KR20210070320A (en) | 2021-06-14 |
| CN111295372A (en) | 2020-06-16 |
| EP3858814A1 (en) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202103134TA (en) | Nitroxoline prodrug and use thereof | |
| IL278171A (en) | Gip derivatives and uses thereof | |
| IL285178A (en) | Compounds and uses thereof | |
| GB201803568D0 (en) | Novel compounds and uses | |
| IL285177A (en) | Compounds and uses thereof | |
| GB201805453D0 (en) | Novel use | |
| IL277502A (en) | Compounds and uses thereof | |
| IL286497A (en) | Compounds and uses thereof | |
| IL284514A (en) | Halo-allylamine compounds and use thereof | |
| IL277749A (en) | Pladienolide compounds and their use | |
| IL291499A (en) | Aza-quinoline compounds and uses thereof | |
| IL279483A (en) | Cyanotriazole compounds and uses thereof | |
| IL280644A (en) | Magnesium-serinate compound and use thereof | |
| IL284764A (en) | Compounds and uses thereof | |
| IL285118A (en) | Compounds and uses thereof | |
| GB201812078D0 (en) | Novel compounds and their uses | |
| SG11202103533UA (en) | Alkoxybenzaldehyde derivatives and precursors thereof | |
| GB201801102D0 (en) | New compounds and uses | |
| IL280369A (en) | New myokines and uses thereof | |
| GB201806349D0 (en) | New compounds and uses | |
| IL283540A (en) | Dock1-inhibiting compound and use thereof | |
| ZA202201239B (en) | Aminothiolester compounds and uses thereof | |
| GB201813311D0 (en) | Novel compounds and their use | |
| GB201810667D0 (en) | New compounds and uses | |
| EP3765454C0 (en) | Antiviral compounds and use thereof |